Shifts In Protein Aggregate Stability Define Proteostasis Decline In The Aging Human Brain

Aging Theory
Aging Pathway
Therapeutic
Analytical
Brain aging involves a non-uniform accumulation of protein aggregates, with less stable aggregates increasing significantly from midlife, while the most stable ones decrease.
Author

Gemini

Published

April 10, 2026

As we age, our bodies undergo many changes, and our brains are no exception. A key process in our cells is called proteostasis, which is like a quality control system for proteins, ensuring they are correctly made, folded, and removed when damaged. When this system falters, proteins can misfold and clump together, forming what are known as protein aggregates. These aggregates are a common feature of aging and are strongly linked to neurodegenerative diseases like Alzheimer’s.

Recent research has shed new light on how these protein aggregates behave in the aging human brain. It turns out that brain aging doesn’t lead to a simple, uniform buildup of all types of protein aggregates. Instead, there’s a complex shift in the types of aggregates present. The most stable protein clumps actually decrease significantly as we get older. However, a different kind of aggregate, those with intermediate stability, start to accumulate progressively from middle age and their accumulation speeds up considerably after the age of 80. Interestingly, these intermediate-stability aggregates are particularly prone to forming liquid-like droplets within cells and are found in the characteristic plaques and tangles seen in Alzheimer’s disease.

The study also found that the efficiency of our cells’ protein-recycling machinery, called proteasomes, and the availability of helper proteins known as chaperones, are strong indicators of how many of these problematic aggregates an individual will accumulate. This suggests that maintaining the health of these cellular systems could be crucial. These discoveries highlight that the way proteins aggregate changes significantly with age and point towards potential new strategies for developing treatments that could target these specific protein quality control pathways to combat age-related brain decline and neurodegenerative diseases.


Source: link to paper